ArticleFrontiers in neurology
Real-world efficacy and safety of Tenecteplase versus Alteplase in acute ischemic stroke: a propensity score-matched analysis.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Real-world evidence comparing Tenecteplase and Alteplase for acute ischemic stroke (AIS) remains limited. This study aimed to evaluate the comparative efficacy and safety of these thrombolytic agents in an unselected patient cohort. Methods: This single-center retrospective study analyzed AIS patients undergoing reperfusion therapy. Propensity score matching (PSM) was employed to balance baseline covariates between Tenecteplase and Alteplase groups. The primary outcome was functional independence (modified Rankin Scale 0-2) at 90 days. Safety endpoints included symptomatic intracranial hemorrhage (sICH) and mortality. Results: Among 371 eligible patients, 68 (18.3%) received Tenecteplase. In the matched cohort, Tenecteplase demonstrated comparable efficacy to Alteplase regarding functional independence ( Conclusion: Tenecteplase exhibits a non-inferior efficacy and safety profile compared to Alteplase in a real-world setting characterized by high baseline stroke severity. These findings support Tenecteplase as a practical and effective therapeutic alternative for routine AIS management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.